Zacks Investment Research upgraded shares of Mast Therapeutics Inc (NASDAQ:MSTX) from a sell rating to a buy rating in a research note released on Friday morning. The brokerage currently has $0.25 target price on the stock.
According to Zacks, “Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California. “
Several other research analysts have also weighed in on MSTX. Maxim Group restated a buy rating and set a $5.00 price objective on shares of Mast Therapeutics in a research note on Thursday, June 9th. Roth Capital restated a buy rating and set a $8.00 price objective on shares of Mast Therapeutics in a research note on Thursday, June 9th. Laidlaw lowered shares of Mast Therapeutics from a buy rating to a neutral rating in a research note on Wednesday, September 21st. Canaccord Genuity restated a buy rating and set a $3.00 price objective on shares of Mast Therapeutics in a research note on Thursday, July 28th. Finally, Cowen and Company lowered shares of Mast Therapeutics from an outperform rating to a market perform rating in a research note on Friday, September 23rd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $2.56.
Mast Therapeutics (NASDAQ:MSTX) opened at 0.1137 on Friday. The company has a 50-day moving average of $0.43 and a 200 day moving average of $0.37. Mast Therapeutics has a 52-week low of $0.10 and a 52-week high of $0.71. The firm’s market cap is $24.08 million.
Mast Therapeutics (NASDAQ:MSTX) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities research analysts anticipate that Mast Therapeutics will post ($0.21) EPS for the current year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. increased its stake in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned about 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent filing with the SEC.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.